Therapeutic vaccines for substance dependence

References

• McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.JANIA 284,1689-1695 (2000). US Department of Health and Human Services. Nicotine addiction: health consequences of smoking. DHHS (1999).
   Google Scholar
• CDC. MMWR — Annual Smoking-attributable mortality, years of potential life lost, and economic costs — Unites States, 1995-1999,51 (2002).
   Google Scholar
• Johnston LD, O'Malley PM, Bachman JG. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2002. NIH Publication No. 03–5374. MD, USA. Nad Inst. Drug Abuse (2003).
   Google Scholar
• SA/VIHSA, Office of Applied Studies. Emergency Department trends from the Drug Abuse Warning Network, Final Estimates 1995–2002, DAWN Series: D-24, DHHS Publication No. (SMA) 03–3780, MD, USA (2003).
   Google Scholar
• O'Brien CPA range of research-based pharmacotherapies for addiction [see comments]. Science 278(5335), 66–70 (1997).
   Google Scholar
• Hart C, McCance-Katz EF, Kosten TR Pharmacotherapies used in common substance use disorders. In: Relapse and Recovery in Addictions. Tims FM, Leukefeld CG, Platt JJ (Eds.), Yale University Press, CT, USA 303–333 (2001).
   Google Scholar
• Gonzalez G, Oliveto A, Kosten TR Treatment of heroin (diamorphine) addiction. Drugs 62,1331–1343 (2002).
   PubMed Web of Science ®Google Scholar
• Balster RE, Schuster CR Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J. E. AnaL Behav. 20,119–129 (1973).
   PubMed Web of Science ®Google Scholar
• Fox BS, Kantak KM, Edwards MA et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. 2(10), 1129–1132 (1996).
   PubMed Web of Science ®Google Scholar
• Koetzner L, Deng S, Sumpter TL et al. Titer-dependent antagonism of cocaine following active immunization in Rhesus Monkeys." Pharmacol. Exp. Then 296(3), 789–796 (2001).
   Google Scholar
• Kosten TR Drugs of abuse. In: Basic and Clinical Pharmacology (8th Ed.) Katzung GB (Ed.), Appleton 8c Lange, CT, USA 532–547 (2000).
   Google Scholar
• Hardin JS, Wessinger WD, Wenger GR et al. A single dose of monoclonal anti—phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats." Pharmacol. Exp. Then 302(1), 119–126 (2002).
   Google Scholar
• ••Demonstrates the very long actingantiphencyclidine effect from a single dose of monoclonal antibody.
   Google Scholar
• De Prada P Winger G, Landry DW Application of artificial enzymes to the problem of cocaine. Ann. NY Acad. Sci. 909,159–169 (2000).
   PubMed Web of Science ®Google Scholar
• Cashman JR, Berkman CE, Underiner GE. Catalytic antibodies that hydrolyze (—)cocaine obtained by a high-throughput procedure.' Pharmacol. E. Then 293(3), 952–961 (2000).
   Google Scholar
• Matsushita M, Hoffman TZ Ashley JA et al. Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg. Med Chem. Lett. 11(2), 87–90 (2001).
   Google Scholar
• Yang G, Chun J, Arakawa-Uramoto H et al. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity." Am. Chem. Soc. 118, 5881–5890 (1996).
   Google Scholar
• Mets B, Winger G, Cabrera C et al. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc. Natl Acad. Sci. USA 95(17), 10176-10181(1998).
   Google Scholar
• Briscoe RJ, Jeanville PM, Cabrera C et al. A catalytic antibody against cocaine attenuates cocaine's cardiovascular effects in mice: a dose and time course analysis. Int. Immunopharmacol. 1,1189–1198 (2001).
   PubMed Web of Science ®Google Scholar
• Kantak KM. Vaccines against drugs of abuse: a viable treatment option? Drugs 63(4), 341–352 (2003).
   Google Scholar
• Schabacker DS, Kirschbaum KS, Segre M. Exploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Abl) capable of inducing Ab213 anti-idiotypic antibodies. Immunology 100(1), 48–56 (2000).
   Google Scholar
• Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR Changes in heroin self-administration by a rhesus monkey after morphine immunization. Nature 252,708–710 (1974).
   PubMed Web of Science ®Google Scholar
• Killian A, Bonese K, Rothberg RM, Wainer BH, Schuster CR Effects of passive immunization against morphine on heroin self-administration. Pharmaca Biochem. Behav. 9,347–352 (1978).
   PubMed Web of Science ®Google Scholar
• Pentel PR, Malin DH, Ennifar S et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 65(1), 191–198 (1999).
   Google Scholar
• Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int. J. Immunopharmacot 22(10), 809–819 (2000).
   Google Scholar
• Hieda Y, Keyler DE, VanDeVoort JT et aZ Active immunization alters the plasma nicotine concentration in rats. J. Pharmaca Exp. Then 283(3), 1076–1081 (1997).
   Google Scholar
• Hieda Y, Keyler DE, VanDeVoort JT et al. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology 143(2), 150–157 (1999).
   PubMed Web of Science ®Google Scholar
• de Villiers SHL, Lindelom N, Kalayanov G et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 69,247–253 (2002).
   PubMed Web of Science ®Google Scholar
• Keyler DE, Shoeman D, LeSage G, Calvin AD, Pentel PR Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J. Pharmaca Exp. Then 305,587–592 (2003).
   PubMed Web of Science ®Google Scholar
• ••Demonstrates protection of the fetus aftermaternal vaccination against nicotine.
   Google Scholar
• Malin DH, Alvarado CL, Woodhouse KS et al. Passive immunization against nicotine attenuates nicotine discrimination. Life Sci. 70,2793–2798 (2002).
   PubMed Web of Science ®Google Scholar
• Malin DH, Lake JR, Lin A et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmaca Biochem. Behav. 68(1), 87–92 (2001).
   Google Scholar
• Tuncok Y, Hieda Y, Keyler DE et a/. Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. E. Clin. Psychopharmacd 9,228–234(2001).
   Google Scholar
• Pentel PR Vaccines and depot medications for drug addiction: rationale, mechanisms of action, and treatment implications. In: Immunotherapies and Depot Medications Jr Substance Dependence. National Academy Press, DC, USA (In Press).
   Google Scholar
• Carrera MR Ashley JA, Parsons LH et al. Suppression of psychoactive effects of cocaine by active immunization. Natur 378(6558), 727–730 (1995).
   PubMed Web of Science ®Google Scholar
• Kantak KM, Collins SL, Lipman EG et al. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl). 148(3), 251–262 (2000). Demonstrates a behavioral effect of an anticocaine vaccine in animal drug self administration.
   Google Scholar
• Carrera MR, Ashley JA, Wirsching P, Koob GF, Janda KD. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Nad Acad. Sci. USA 98(4), 1988-1992 (2001).
   Google Scholar
• Carrera MR, Ashley JA, Zhou B et al. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl Acad. Sci. USA 97(11), 6202–6206 (2000).
   Google Scholar
• ••Demonstrates a behavioral effect of ananticocaine vaccine in animal drug relpase model.
   Google Scholar
• Baird TJ, Deng SX, Landry DW, Winger G, Woods JH. Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats.' Pharmacot E. Then 295(3), 1127-1134(2000).
   Google Scholar
• Johnson MW Ettinger RI-I. Active cocaine immunization attenuates the discriminative properties of cocaine. E. Clin. Psychopharmacot 8(2), 163–167 (2000).
   Google Scholar
• Owens SM, Mayershohn M. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab. Dispos. 14(1), 52–58 (1986).
   PubMed Web of Science ®Google Scholar
• Proksch JW, Gentry \VB, Owens SM. Anti- phencydidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J. Pharmacd E. Then 292(3), 831–837 (2000).
   Google Scholar
• Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, Owens SM. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.' Pharmitcd E. Then 278(2), 709–716 (1996).
   Google Scholar
• Valentine JD, Hokanson JS, Matta SG, Sharp BM. Self-administration in rats allowed unlimited access to nicotine. Psychopharmacology (Berl.) 133(3), 300–304 (1997).
   Google Scholar
• Valentine JL, Owens SM. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J. PharrnacoZ E. Ther. 278(2), 717-724(1996).
   Google Scholar
• Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, Pentel PR Tissue-dependent effects of immunization with a nicotine conjuage vaccine on the distribution of nicotine in rats. Int. Immunopharmacot 3,957–970 (2003).
   PubMed Web of Science ®Google Scholar
• Byrnes-Blake KA, Carroll Fl, Abraham Owens SM. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int. Immunopharmacol. 1,329–338 (2001).
   Google Scholar
• McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behav. Pharmacol. 13,465–473 (2002).
   Google Scholar
• Byrnes-Blake KA, Laurenzana EM, Carroll FT et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur. Pharmaca 461,119–128 (2003).
   PubMed Web of Science ®Google Scholar
• Kosten TR, Rosen M, Bond J et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20,1196–1204 (2002).
   PubMed Web of Science ®Google Scholar
• ••First human study of a cocaine vaccineshowing good immungenicity and safety.
   Google Scholar
• Jertbom M, Svennerholm A-M, Holmgren J. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 10(2), 130–132 (1992).
   PubMed Web of Science ®Google Scholar
• Owens SM, Pentel P, Kosten TR Immunotherapies for substance abuse. Procedings of College on Problems of Drug Dependence, 2003. 1VIDA Research Monograph, MD, USA (In Press).
   Google Scholar
• Alterman AT, McKay JR, Mulvaney FD, McLellan AT. Prediction of attrition from day hospital treatment in lower socioeconomic cocaine-dependent men. DrugAlcohol Depend 40(3), 227–233 (1996).
   PubMed Web of Science ®Google Scholar
• Kang S, Kleinman PH, Woody GE et al. Outcomes for cocaine abusers after once-a-week psychosocial therapy. Am. J. Psyca 148,630–635 (1991).
   PubMed Web of Science ®Google Scholar
• San L, Pomarol G, Peri JM, 011e JM, Carni J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br I Add 86,983–990 (1991).
   Google Scholar
• Jaffe JH, Cascella NG, Kumor KM, Sherer MA. Cocaine induced (ICA ine craving. Psychopharmacology (Berl). 97,59–64 (1989).
   PubMed Web of Science ®Google Scholar